APAC Anti-Hypertensive Therapeutics Market will be valued at 19.9 billion in 2021

Anti- hypertensive Therapeutics in Asia- Pacific
Markets to 2021- Increasing Prevalence of
Hypertension Drives Market Growth despite
Weak Pipeline
Published on – 01 July, 2015 | Number of pages : 82
Single User Price: $4995
“Hypertension is a chronic medical condition characterized by elevated blood
pressure in the arteries. It affected an estimated 517 million people in 2014,
a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to
561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India,
Australia, and Japan.”

Summary of the Report:
Hypertension is a chronic medical condition characterized by elevated blood pressure in the
arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a
Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific
(APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial
contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of
hypertension is low among physicians, patients, and the public alike, leading to poor blood
pressure control.
The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme
Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), betablockers,
renin inhibitors, and diuretics. The percentage of patients treated using monotherapy
and combination therapy (including fixed-dose combinations) varies from country to country. The
most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the
leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan
medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril,
fosinopril, trandolapril, and quinapril dominate the ACEIs.
Click Here To Check Complete Report

Scope of the Report:
Hypertension prevalence is a prominent contributor to market size in the assessed
countries. The market is mostly dominated by generics, and there are only a few patented
products.
Will generics continue to dominate treatment?
How do the elderly populations and their associated risk factors affect prevalence?
The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules
in various stages of development, dominated by small molecules.
Will the upcoming molecules change the treatment paradigm in the near future?
How will the weak pipeline affect the market?
Analysis of clinical trials since 2006 identified that anti-hypertensive products have a
high rate of attrition.
How do failure rates vary by product stage of development, molecule type, and
mechanism of action?
How do other factors such as average trial duration and trial size influence the costs and
risks associated with product development?
Over the 2014–2021 forecast period, the APAC anti-hypertensive therapeutics market is
expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9
billion. Growth is projected to vary considerably across the four assessed markets.
Download
Sample Brochure

Reasons to buy:
This report will enable you to -
Understand the clinical context of hypertension by considering symptoms, etiology,
pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and
treatment options.
Identify the therapeutic strategies, products, and companies that dominate the current
marketed products landscape, and recognize gaps.
Appreciate key anti-hypertensive pipeline trends in molecule type, administration route,
mechanism of action, and novelty.
Consider market opportunities and potential risks by examining trends in antihypertensive
clinical trial size, duration, and failure rate by stage of development,
molecule type, and mechanism of action.
Compare treatment usage patterns, annual therapy costs, and market growth projections
for the China, India, Australia, and Japan.
Discover trends in licensing and co-development deals concerning anti-hypertensive
products and identify the major strategic consolidations that have shaped the
commercial landscape.
Make an Inquiry
Before Buying

Anti- hypertensive Therapeutics in Asia- Pacific Markets to
2021- Increasing Prevalence of Hypertension Drives
Market Growth despite Weak Pipeline
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of the APAC Anti-Hypertensive Therapeutics Market are provided in the
report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click here to order a copy of APAC
Anti-Hypertensive Therapeutics
Market Report